» Articles » PMID: 21253575

Distinct Patterns of IFITM-mediated Restriction of Filoviruses, SARS Coronavirus, and Influenza A Virus

Abstract

Interferon-inducible transmembrane proteins 1, 2, and 3 (IFITM1, 2, and 3) are recently identified viral restriction factors that inhibit infection mediated by the influenza A virus (IAV) hemagglutinin (HA) protein. Here we show that IFITM proteins restricted infection mediated by the entry glycoproteins (GP(1,2)) of Marburg and Ebola filoviruses (MARV, EBOV). Consistent with these observations, interferon-β specifically restricted filovirus and IAV entry processes. IFITM proteins also inhibited replication of infectious MARV and EBOV. We observed distinct patterns of IFITM-mediated restriction: compared with IAV, the entry processes of MARV and EBOV were less restricted by IFITM3, but more restricted by IFITM1. Moreover, murine Ifitm5 and 6 did not restrict IAV, but efficiently inhibited filovirus entry. We further demonstrate that replication of infectious SARS coronavirus (SARS-CoV) and entry mediated by the SARS-CoV spike (S) protein are restricted by IFITM proteins. The profile of IFITM-mediated restriction of SARS-CoV was more similar to that of filoviruses than to IAV. Trypsin treatment of receptor-associated SARS-CoV pseudovirions, which bypasses their dependence on lysosomal cathepsin L, also bypassed IFITM-mediated restriction. However, IFITM proteins did not reduce cellular cathepsin activity or limit access of virions to acidic intracellular compartments. Our data indicate that IFITM-mediated restriction is localized to a late stage in the endocytic pathway. They further show that IFITM proteins differentially restrict the entry of a broad range of enveloped viruses, and modulate cellular tropism independently of viral receptor expression.

Citing Articles

Alternative splicing expands the antiviral IFITM repertoire in Chinese rufous horseshoe bats.

Mak N, Liu J, Zhang D, Taylor J, Li X, Rahman K PLoS Pathog. 2024; 20(12):e1012763.

PMID: 39724110 PMC: 11801718. DOI: 10.1371/journal.ppat.1012763.


SARS-CoV-2 S protein disrupts the formation of ISGF3 complex through conserved S2 subunit to antagonize type I interferon response.

Cai Z, Ni W, Li W, Wu Z, Yao X, Zheng Y J Virol. 2024; 99(1):e0151624.

PMID: 39699185 PMC: 11784297. DOI: 10.1128/jvi.01516-24.


Exploring the shared pathogenic mechanisms of tuberculosis and COVID-19: emphasizing the role of VNN1 in severe COVID-19.

Sun P, Wang Y, Zhou S, Liang J, Zhang B, Li P Front Cell Infect Microbiol. 2024; 14:1453466.

PMID: 39639868 PMC: 11618882. DOI: 10.3389/fcimb.2024.1453466.


Antiviral Effects of Avian Interferon-Stimulated Genes.

He X, Zhang S, Zou Z, Gao P, Yang L, Xiang B Animals (Basel). 2024; 14(21).

PMID: 39518785 PMC: 11545081. DOI: 10.3390/ani14213062.


IFITM1 is a host restriction factor that inhibits porcine epidemic diarrhea virus infection.

Cheng J, He J, Feng S, Tan L, Bai B, Dong W J Nanobiotechnology. 2024; 22(1):677.

PMID: 39501328 PMC: 11536902. DOI: 10.1186/s12951-024-02884-9.


References
1.
Lange U, Saitou M, Western P, Barton S, Surani M . The fragilis interferon-inducible gene family of transmembrane proteins is associated with germ cell specification in mice. BMC Dev Biol. 2003; 3:1. PMC: 153542. DOI: 10.1186/1471-213x-3-1. View

2.
Kuhn J, Radoshitzky S, Guth A, Warfield K, Li W, Vincent M . Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem. 2006; 281(23):15951-8. DOI: 10.1074/jbc.M601796200. View

3.
Belouzard S, Chu V, Whittaker G . Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A. 2009; 106(14):5871-6. PMC: 2660061. DOI: 10.1073/pnas.0809524106. View

4.
Becker M, Graham R, Donaldson E, Rockx B, Sims A, Sheahan T . Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl Acad Sci U S A. 2008; 105(50):19944-9. PMC: 2588415. DOI: 10.1073/pnas.0808116105. View

5.
Moffatt P, Gaumond M, Salois P, Sellin K, Bessette M, Godin E . Bril: a novel bone-specific modulator of mineralization. J Bone Miner Res. 2008; 23(9):1497-508. DOI: 10.1359/jbmr.080412. View